|
Novo Nordisk Expands DTC Push With New Wegovy Subscription Program
|
Written by: J. Smith |
Hits: 246
|
|
FDA Approves Awiqli as First Once-Weekly Basal Insulin for Type 2 Diabetes
|
Written by: J. Smith |
Hits: 320
|
|
Retatrutide’s First Phase 3 Diabetes Results Draw Attention for More Than Strong Numbers
|
Written by: J. Smith |
Hits: 514
|
|
FDA Approves Wegovy HD, Adding a Higher-Dose Semaglutide Option for Obesity
|
Written by: J. Smith |
Hits: 348
|
|
Zealand Pharma Reports Phase 2 Results for Petrelintide
|
Written by: J. Smith |
Hits: 355
|
|
REDEFINE-4 Results: What They Mean for Patients
|
Written by: J. Smith |
Hits: 307
|
|
Novo Nordisk Renames Oral Semaglutide as Ozempic Pill Ahead of U.S. Launch
|
Written by: J. Smith |
Hits: 417
|
|
Wegovy Oral Pill Launches in United States
|
Written by: J. Smith |
Hits: 436
|
|
FDA Approves First Oral GLP-1 for Chronic Weight Management
|
Written by: J. Smith |
Hits: 455
|
|
Retatrutide Delivers Phase 3 Success and Signals Lilly’s Strategic Positioning
|
Written by: J. Smith |
Hits: 796
|
